Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT06248697 Recruiting - Solid Tumor Clinical Trials

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

Start date: January 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 and CTLA-4 nanobodies (αPD1/CTLA-4-MSLN-CAR T cells) in patients with solid tumors.

NCT ID: NCT06245330 Recruiting - Pancreatic Cancer Clinical Trials

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

NCT ID: NCT06241898 Recruiting - Solid Tumor Clinical Trials

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Start date: October 1, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: - to assess the safety and tolerability of BB-1709. - to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709

NCT ID: NCT06239623 Recruiting - Melanoma Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

JSI-1187-101 phase 1 study

NCT ID: NCT06237413 Recruiting - Solid Tumor Clinical Trials

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Start date: August 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.

NCT ID: NCT06234423 Recruiting - Ovarian Cancer Clinical Trials

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Start date: February 9, 2024
Phase: Phase 1
Study type: Interventional

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

NCT ID: NCT06234098 Recruiting - Solid Tumor Clinical Trials

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Start date: February 13, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.

NCT ID: NCT06220318 Recruiting - Solid Tumor Clinical Trials

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Start date: July 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

NCT ID: NCT06210815 Recruiting - Solid Tumor Clinical Trials

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

NCT ID: NCT06209385 Recruiting - Solid Tumor Clinical Trials

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Start date: August 11, 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors